Cargando…

Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast

Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Piguo, Xia, Chen, Yang, Yifeng, Lei, Wang, Yang, Weiping, Yu, Junhua, Ji, Yishun, Ren, Lijun, Ye, Fugui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289843/
https://www.ncbi.nlm.nih.gov/pubmed/34282256
http://dx.doi.org/10.1038/s41598-021-94351-w
_version_ 1783724376300978176
author Gong, Piguo
Xia, Chen
Yang, Yifeng
Lei, Wang
Yang, Weiping
Yu, Junhua
Ji, Yishun
Ren, Lijun
Ye, Fugui
author_facet Gong, Piguo
Xia, Chen
Yang, Yifeng
Lei, Wang
Yang, Weiping
Yu, Junhua
Ji, Yishun
Ren, Lijun
Ye, Fugui
author_sort Gong, Piguo
collection PubMed
description Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for inclusion in the analysis. Median age at diagnosis was 56 years (range 2–96 years). Both sexes and bilateral breast could be affected. Intriguingly, the incidence of SCB tended towards to decreasing in recent decades. Small tumor burden was observed with a mean tumor size of 2.13 cm. In a subgroup with sufficient details, positive staining of estrogen receptor (ER) and progesterone receptor (PR) was 58% and 40%, respectively. The vast majority of patients were of well to moderate differentiation (86.86%) and negative regional lymph nodes involvement (70.71%). Nearly half of the patients took radiotherapy and chemotherapy. Seniors were inclined to have an inferior breast cancer specific survival (BCSS) than their younger counterparts (P = 0.018). Patients underwent breast conserving surgery (BCS) and radiotherapy had much better BCSS than its mastectomy counterparts (P = 0.014). Collectively, SCB is a clinical indolent invasive breast cancer with excellent prognosis. BCS in conjunction with radiotherapy would be a rational alternative for this distinct entity.
format Online
Article
Text
id pubmed-8289843
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82898432021-07-21 Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast Gong, Piguo Xia, Chen Yang, Yifeng Lei, Wang Yang, Weiping Yu, Junhua Ji, Yishun Ren, Lijun Ye, Fugui Sci Rep Article Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for inclusion in the analysis. Median age at diagnosis was 56 years (range 2–96 years). Both sexes and bilateral breast could be affected. Intriguingly, the incidence of SCB tended towards to decreasing in recent decades. Small tumor burden was observed with a mean tumor size of 2.13 cm. In a subgroup with sufficient details, positive staining of estrogen receptor (ER) and progesterone receptor (PR) was 58% and 40%, respectively. The vast majority of patients were of well to moderate differentiation (86.86%) and negative regional lymph nodes involvement (70.71%). Nearly half of the patients took radiotherapy and chemotherapy. Seniors were inclined to have an inferior breast cancer specific survival (BCSS) than their younger counterparts (P = 0.018). Patients underwent breast conserving surgery (BCS) and radiotherapy had much better BCSS than its mastectomy counterparts (P = 0.014). Collectively, SCB is a clinical indolent invasive breast cancer with excellent prognosis. BCS in conjunction with radiotherapy would be a rational alternative for this distinct entity. Nature Publishing Group UK 2021-07-19 /pmc/articles/PMC8289843/ /pubmed/34282256 http://dx.doi.org/10.1038/s41598-021-94351-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Gong, Piguo
Xia, Chen
Yang, Yifeng
Lei, Wang
Yang, Weiping
Yu, Junhua
Ji, Yishun
Ren, Lijun
Ye, Fugui
Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast
title Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast
title_full Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast
title_fullStr Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast
title_full_unstemmed Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast
title_short Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast
title_sort clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289843/
https://www.ncbi.nlm.nih.gov/pubmed/34282256
http://dx.doi.org/10.1038/s41598-021-94351-w
work_keys_str_mv AT gongpiguo clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT xiachen clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT yangyifeng clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT leiwang clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT yangweiping clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT yujunhua clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT jiyishun clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT renlijun clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast
AT yefugui clinicopathologicprofilingandoncologicoutcomesofsecretorycarcinomaofthebreast